We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
Read MoreHide Full Article
Key Takeaways
{\"0\":\"Nektar\'s Q2 loss of $2.95 per share and revenues beat estimates.\",\"1\":\"Revenues fell after the 2024 sale of the Huntsville facility, ending product revenue streams.\",\"2\":\"Phase IIb trials on rezpeg for atopic dermatitis and alopecia areata are moving forward.\"}
Nektar Therapeutics (NKTR - Free Report) reported a loss of $2.95 per share for the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $3.13. In the year-ago quarter, the company had reported a loss of $3.76 per share.
Excluding the impact of non-cash loss from NKTR’s equity method investment in Gannet BioChem, the company incurred an adjusted loss of $2.78 per share in the second quarter of 2025 compared with an adjusted loss of $2.85 per share in the year-ago quarter.
Total revenues in the second quarter decreased 52.4% year over year to $11.2 million. The reported figure marginally beat the Zacks Consensus Estimate of $11 million.
The year-over-year revenue decrease was due to the sale of the Huntsville manufacturing facility in December 2024, following which the company no longer records product revenues. Nektar’s top line currently comprises non-cash royalty revenues.
Shares of Nektar have rallied 56% so far this year compared with the industry’s rise of 5.5%.
Image Source: Zacks Investment Research
NKTR's Q2 Earnings in Detail
Research and development (R&D) expenses were $29.9 million, up around 0.7% year over year.
General and administrative (G&A) expenses decreased around 16.6% year over year to $17.1 million.
As of June 30, 2025, Nektar had cash and cash equivalents and marketable securities worth $175.9 million compared with $220.7 million as of March 31, 2025.
NKTR's Recent Pipeline Updates
Nektar’s lead pipeline candidate, rezpegaldesleukin (rezpeg), is being developed as a self-administered injection for several autoimmune and inflammatory diseases.
Two separate phase IIb studies are evaluating rezpeg for treating atopic dermatitis and alopecia areata.
In June 2025, NKTR announced that the phase IIb REZOLVE-AD study evaluating rezpeg, in patients with moderate-to-severe atopic dermatitis, met its primary and key secondary endpoints.
Besides atopic dermatitis, the company is also investigating rezpeg in the phase IIb REZOLVE-AA study for treating patients with severe-to-very severe alopecia areata. Top-line data from the same is expected in December 2025.
Last month, the FDA granted a Fast Track designation to rezpeg for the treatment of severe-to-very severe alopecia areata. The regulatory body previously granted a Fast Track designation to rezpeg for the treatment of moderate-to-severe atopic dermatitis.
Nektar regained full rights to rezpeg from pharma giant Eli Lilly (LLY - Free Report) in April 2023 and took charge of its clinical development. Rezpeg was earlier developed in collaboration with Lilly for several autoimmune indications.
Rezpeg is now a wholly owned asset of Nektar, and the company owes no royalty payments to LLY.
Nektar Therapeutics Price, Consensus and EPS Surprise
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 33.4%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 8.3% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
Key Takeaways
Nektar Therapeutics (NKTR - Free Report) reported a loss of $2.95 per share for the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $3.13. In the year-ago quarter, the company had reported a loss of $3.76 per share.
Excluding the impact of non-cash loss from NKTR’s equity method investment in Gannet BioChem, the company incurred an adjusted loss of $2.78 per share in the second quarter of 2025 compared with an adjusted loss of $2.85 per share in the year-ago quarter.
Total revenues in the second quarter decreased 52.4% year over year to $11.2 million. The reported figure marginally beat the Zacks Consensus Estimate of $11 million.
The year-over-year revenue decrease was due to the sale of the Huntsville manufacturing facility in December 2024, following which the company no longer records product revenues. Nektar’s top line currently comprises non-cash royalty revenues.
Shares of Nektar have rallied 56% so far this year compared with the industry’s rise of 5.5%.
Image Source: Zacks Investment Research
NKTR's Q2 Earnings in Detail
Research and development (R&D) expenses were $29.9 million, up around 0.7% year over year.
General and administrative (G&A) expenses decreased around 16.6% year over year to $17.1 million.
As of June 30, 2025, Nektar had cash and cash equivalents and marketable securities worth $175.9 million compared with $220.7 million as of March 31, 2025.
NKTR's Recent Pipeline Updates
Nektar’s lead pipeline candidate, rezpegaldesleukin (rezpeg), is being developed as a self-administered injection for several autoimmune and inflammatory diseases.
Two separate phase IIb studies are evaluating rezpeg for treating atopic dermatitis and alopecia areata.
In June 2025, NKTR announced that the phase IIb REZOLVE-AD study evaluating rezpeg, in patients with moderate-to-severe atopic dermatitis, met its primary and key secondary endpoints.
Besides atopic dermatitis, the company is also investigating rezpeg in the phase IIb REZOLVE-AA study for treating patients with severe-to-very severe alopecia areata. Top-line data from the same is expected in December 2025.
Last month, the FDA granted a Fast Track designation to rezpeg for the treatment of severe-to-very severe alopecia areata. The regulatory body previously granted a Fast Track designation to rezpeg for the treatment of moderate-to-severe atopic dermatitis.
Nektar regained full rights to rezpeg from pharma giant Eli Lilly (LLY - Free Report) in April 2023 and took charge of its clinical development. Rezpeg was earlier developed in collaboration with Lilly for several autoimmune indications.
Rezpeg is now a wholly owned asset of Nektar, and the company owes no royalty payments to LLY.
Nektar Therapeutics Price, Consensus and EPS Surprise
Nektar Therapeutics price-consensus-eps-surprise-chart | Nektar Therapeutics Quote
NKTR's Zacks Rank & Stocks to Consider
Nektar currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are CorMedix (CRMD - Free Report) and Immunocore (IMCR - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
In the past 60 days, estimates for CorMedix’s earnings per share have increased from 93 cents to 97 cents for 2025. During the same time, earnings per share estimates for 2026 have increased from $1.64 to $1.65. Year to date, shares of CRMD have rallied 33.4%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 25.82%.
In the past 60 days, estimates for Immunocore’s 2025 loss per share have narrowed from 86 cents to 68 cents. Loss per share estimates for 2026 have narrowed from $1.34 to $1.10 during the same period. IMCR stock has increased 8.3% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 76.18%.